These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32150880)

  • 1. Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for
    La Rocca F; Grieco V; Ruggieri V; Zifarone E; Villani O; Zoppoli P; Russi S; Laurino S; Falco G; Calice G; Marinaccio A; Natalicchio MI; Albano F; Musto P
    Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32150880
    [No Abstract]   [Full Text] [Related]  

  • 2. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
    Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
    Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
    Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
    Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2 V617F mutation can be reliably detected in serum using droplet digital PCR.
    Nystrand CF; Ghanima W; Waage A; Jonassen CM
    Int J Lab Hematol; 2018 Apr; 40(2):181-186. PubMed ID: 29150911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.
    Link-Lenczowska D; Pallisgaard N; Cordua S; Zawada M; Czekalska S; Krochmalczyk D; Kanduła Z; Sacha T
    Ann Hematol; 2018 Dec; 97(12):2299-2308. PubMed ID: 30056580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR.
    Lu Y; Lin L; Lin J; Wu B; Cai G; Wang X; Ma X
    Ann Hematol; 2024 Sep; 103(9):3553-3562. PubMed ID: 39043913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.
    Kinz E; Leiherer A; Lang AH; Drexel H; Muendlein A
    Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory-developed Droplet Digital PCR Assay for Quantification of the JAK2
    Liu Y; Han C; Li J; Xu S; Xiao Z; Guo Z; Rao S; Yao Y
    Glob Med Genet; 2024 Jun; 11(2):132-141. PubMed ID: 38585044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms.
    Fontanelli G; Baratè C; Ciabatti E; Guerrini F; Grassi S; Del Re M; Morganti R; Petrini I; Arici R; Barsotti S; Metelli MR; Danesi R; Galimberti S
    Int J Lab Hematol; 2015 Dec; 37(6):766-73. PubMed ID: 26189968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Has Higher Proportion of Janus Kinase 2 V617F Mutation Compared to Paired EDTA-Whole Blood Sample: A Model for Somatic Mutation Quantification Using qPCR and the 2
    Barra GB; Santa Rita TH; Almeida ALSC; Jácomo RH; Nery LFA
    Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32178286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparability of JAK2 p.V617F allele burden in peripheral blood and that in bone marrow in patients with suspected myeloproliferative neoplasms: a single-center prospective study.
    Lu N; Ying L; Zhang X; Chen J; Ding X; Guo Y; Wang W; Chen S; Xu L
    Am J Transl Res; 2023; 15(3):2084-2089. PubMed ID: 37056830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A novel modi cation of real-time AS-qPCR by using locked nucleic acid-modified oligonucleotide probe as wild type allele amplification blockers for quantitative detection of the JAK2 V617F mutation].
    Shao DH; Liang GW; He ML; Cao QY
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):421-5. PubMed ID: 23688754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.
    Rapado I; Albizua E; Ayala R; Hernández JA; Garcia-Alonso L; Grande S; Gallardo M; Gilsanz F; Martinez-Lopez J
    Ann Hematol; 2008 Sep; 87(9):741-9. PubMed ID: 18575865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
    Chae H; Lee JH; Lim J; Jung SW; Kim M; Kim Y; Han K; Cho BS; Cho SG; Lee JW; Min WS
    Korean J Lab Med; 2009 Jun; 29(3):243-8. PubMed ID: 19571623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
    Benati M; Montagnana M; Danese E; De Matteis G; Veneri D; Paviati E; Guidi GC
    Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between JAK2
    Brown R; Jasiakiewicz J; Greer V; Hindley A; McDowell K; Devlin E; Clarke K; Buckley F; Crean C; McGimpsey J; Cuthbert RJG; Cunningham N; Arnold C; Finnegan D; Benson G; McMullin MF; Catherwood MA
    Ir J Med Sci; 2024 Aug; ():. PubMed ID: 39138783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantages of the quenching probe method over other PCR-based methods for detection of the JAK2 V617F mutation.
    Ono A; Okuhashi Y; Takahashi Y; Itoh M; Nara N; Tohda S
    Oncol Lett; 2012 Aug; 4(2):205-208. PubMed ID: 22844354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.